Total
0
Shares
Wellness and Beauty Solutions (ASX:WNB) to sell its self-tanning product at Chemist Warehouse
  • Uscom (UCM) has signed a supply and development agreement with A&D Japan for the Uscom BP+ blood pressure monitor
  • This agreement covers the installation of new technology into Uscom's device as it approaches regulatory approval in China and the United States
  • According to Uscom, BP+ provides a highly accurate and repeatable measurement of central blood pressure and pulse pressure waveforms, which take be used on both the arm and the heart
  • The company says its device performs better than current tech used to manage hypertension, one of the leading causes of premature death in the world
  • Uscom shares are down a slight 4.35 per cent and are trading for 22 cents each

Uscom (UCM) has signed a supply and development agreement with A&D Japan for the Uscom BP+ blood pressure monitor.

A&D (Analogue and Digital) are a Tokyo-based company that is engaged in the development, manufacture, and sale of measurement instruments in the medical and healthcare sector.

This agreement covers the installation of new technology from A&D in Uscom's device as it approaches regulatory approval in China and the United States.

Uscom BP+ is a highly-accurate blood pressure monitor that can measure blood pressure waveforms in not only the arm but the heart.

It provides a highly accurate and repeatable measurement of central blood pressure and pulse pressure waveforms.

According to Uscom, BP+ is set to replace traditional blood pressure monitors and is the up-and-coming standard of care measurements for hypertension, heart failure, and general heart health.

"Current hypertensive management is poor, and we have developed the BP+ to advance the science in this common and dangerous condition," Executive Chairman Associate Professor Rob Phillips stated.

"Quality technology is critical for our devices, and this new partnership with A&D allows Uscom to provide clinicians with the best tools for BP monitoring and hypertensive care," he said.

Hypertension

According to the World Health Organisation (WHO), hypertension is one of the leading causes of premature death in the world.

It has estimated that of the 1.13 billion people who have it, only one in five has it under control.

WHO hopes to reduce the prevalence of hypertension by 25 per cent by 2025.

Hypertension, also known as high blood pressure, is a condition in which the force of the blood against the artery walls in the body is too high.

While hypertension typically has no symptoms, if it's left untreated for a long period of time it can cause health conditions such as a stroke or heart disease.

Treatments include a healthier diet with less salt, quitting smoking, regular exercise, and medication.

Uscom shares are down a slight 4.35 per cent and are trading for 22 cents each at 1:49 pm AEST.


Subscribe


UCM by the numbers
More From The Market Herald
EVE Investment (ASX:EVE) - Managing Director, Bill Fry - The Market Herald

" EVE Investments (ASX:EVE) increases revenue and cash balance in Q1 FY21

Wellness business EVE Investments (EVE) has announced a record start to FY21, increasing both its revenue and cash balance during the September quarter.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech’s (ASX:HCT) Path-Away kills 99.9pc of COVID-19

The coronavirus rollercoaster continues for small-cap biotech company Holista CollTech (HCT) today, with its share price almost doubling on the company’s latest announcement.
Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

" Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO).
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald

" Anteris Technologies (ASX:AVR) one step closer to biologic heart valve

Anteris Technologies (AVR) is continuing to make progress in the development of its DurAVR 3D single-piece aortic valve.